Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Xencor, Inc.NASDAQ: XNCR

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation dips below year-ago levels

Q2 FY2026 stock-based compensation of $9.19M fell 14.4% year over year, behind the +10.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Stock-based compensation amounted to 34.4% of revenue in FY2025, down 13.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -14.4% toward the trailing-twelve-month pace of +10.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$9.19M-3.9% QoQ
Last fiscal yearDec 2025
$43.23M-18.9% YoY
LTMJun 2026
$39.03M+10.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.4%——
1 year-18.9%——
3-year CAGR-4.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
43.23M USD
Year-over-year change
-18.9%
4-year CAGR
+4.0%

Stock-Based Compensation vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.2% is the 2nd highest of 8, against a peer median of -0.7%.
  • Stock-based compensation amounts to 37.2% of revenue for XNCR, versus a peer median of 15.0%.
XNCR Competitors
Stock-Based Compensation for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
XNCRXencor, Inc.LTM Jun 2026$39.03M USD+10.2%-4.0%37.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M USD-0.7%—32869.6%
IMCRImmunocore Holdings plcLTM Mar 2026$28.21M USD+14.1%—7.3%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
NKTRNektar TherapeuticsLTM Jun 2026$11.99M USD-31.8%-39.6%22.0%
ADAGAdagene Inc.LTM Jun 2024$7.27M USD—-29.1%891.4%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
IMMPImmutep LimitedFY2025A$1.16M AUD-35.2%-7.8%23.1%
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
Peer median (excluding XNCR) —-0.7%-9.5%15.0%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income82.63M(55.18M)(133.13M)(236.54M)(91.92M)
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
Deferred Income Tax(18.97M)0000
Stock-Based Compensation36.98M48.91M053.28M43.23M
Change in Working Capital(102.6M)48.87M19.13M(40.4M)47.45M
Accounts Receivables(54.94M)36.86M19.83M(32.67M)28.73M
Inventory1.4M0000
Accounts Payables5.05M(3.91M)3.83M2.85M(3.95M)
Other Working Capital(54.11M)15.92M(4.53M)(10.57M)22.67M
Other Non-Cash Items(22.38M)(26.91M)24.58M9.36M(144.39M)
Operating Cash Flow(16.85M)24.49M(77.93M)(202.19M)(135.12M)
Capital Expenditures(15.98M)(43.4M)(18.45M)(6.1M)(3.15M)
Acquisitions (Net)(2.66M)0501K00
Purchases of Investments(509.6M)(387.93M)(782.91M)(595.05M)(298.9M)
Sales of Investments485.15M306.61M693.09M596.66M427.64M
Other Investing Activities(3.16M)90K0(3.38M)14.39M
Investing Cash Flow(46.25M)(119.73M)(110.57M)(7.87M)139.99M
Debt Repayment00000
Common Stock Issued28.92M05.39M201.26M9.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities14.12M5.7M183.33M(4.1M)(1.73M)
Financing Cash Flow43.04M5.7M188.72M197.15M8.23M
Effect of Forex Changes00(380K)00
Net Change in Cash(20.06M)(89.54M)(152K)(12.91M)13.1M
Free Cash Flow(32.83M)(18.92M)(96.37M)(208.29M)(138.27M)

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.